Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
Détails
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_9633D0FDC5AD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
Périodique
Virchows Archiv
ISSN
0945-6317
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
448
Numéro
1
Pages
35-45
Langue
anglais
Résumé
Hepatocyte paraffin 1 (Hep Par 1) and neprilysin (CD10) are well-known markers of hepatocellular carcinoma (HCC). To assess their potential prognostic role, we conducted a retrospective analysis of 97 formalin-fixed and paraffin-embedded HCC from patients treated by surgery with curative intent, using standard immunohistochemical procedures and semiquantitative analysis. Strong Hep Par 1 expression and canalicular CD10 staining pattern were significantly correlated with smaller tumor size (p=0.007 and 0.04, respectively). On univariate analysis, longer overall survival was observed in patients with strong Hep Par 1 expression (p=0.0005) and in patients with a CD10can staining pattern (p=0.02). On multivariate analysis, the combined immunohistochemical score (CIS) obtained by addition of Hep Par 1 and CD10can scores and subtraction of cytoplasmic CD10 score was retained as the single most important prognostic factor (p=0.001). Patients with a CIS <4 had a 3.5-fold increased risk of death, as compared to those with a CIS >or=4. In conclusion, strong Hep Par 1 expression, presence of CD10can labeling, and absence of CD10cyt staining are favorable prognostic factors in HCC, which can be easily combined into a single immunohistochemical score for routine clinical use.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Hepatocellular, Female, Humans, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Neprilysin, Prognosis, Retrospective Studies, Survival Analysis, Tumor Markers, Biological
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/01/2008 19:35
Dernière modification de la notice
14/02/2022 8:56